Guggenheim lowered the firm’s price target on Axsome Therapeutics to $90 from $105 and keeps a Buy rating on the shares after the company reported Q4 earnings. Newly launched Auvelity is exceeding early Street expectations and the firm has conviction that the drug will continue to outperform, the analyst tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- Axsome Therapeutics reports Q4 EPS ($1.41), consnesus ($1.14)
- Pharmanovia announces in-licensing agreement with Axsome for Sunosi
- Axsome Therapeutics enters license agreement with Pharmanovia
